This div will be replaced


Max International Acquires CellGevity Technology and Assets

We are very excited to announce that Max International has acquired the technology and assets behind CellGevity, a company founded in part by Dr. Herbert Nagasawa after 25 years of scientific research on Glutathione and the benefits it provides the human body.  Max International has acquired all of the assets of CellGevity including:

  • Patents
  • Proprietary Research
  • Breakthrough Formulations
  • Executive Team
  • Research Scientists

What does this mean for Max International?

Max International has long been the leader in glutathione research and this acquisition only further ensures that Max International will remain at the forefront as the undisputed leader in all aspects of the glutathione industry.  The science, formulations and patents associated with CellGevity in conjunction with Max International will provide the public with unprecedented glutathione research and products for years to come. 

Biographies

Herbert T. Nagasawa, Ph.D.: Co-Founder, Chairman and Director of Research

Scott Momii, Co-Founder and CEO

Scott Nagasawa, Pharm.D.  Co-Founder and Chief Technical Officer